What does early access actually mean?
Early access programmes allow patients to access drugs which are not yet fully licenced, but where data suggests they could make a transformative difference to their condition.
Known by many names, including compassionate use, these programmes help to provide vital care to patients while the regulatory process is finalised, and have the potential to provide attentional data and real-world insight into the use of new drugs.
With thanks to:
Resource type
Webinar
Duration
1.5 hours
Last updated
January 2021
Resource type
Webinar
Duration
1.5 hours
Date
January 2021
What will you learn in this webinar?
In this webinar, Beacon, Metabolic Support UK and Bionical Emas outline the basic principles of early access programmes, their value to industry and patients, and the role that patient groups can play in ensuring their establishment and success.
Who is this webinar for?
This webinar is for patient groups who want to learn:
- The basic principles of early access programmes
- Their value to industry and patients
- The role that patient groups can play in ensuring their establishment and success
You may also be interested in…